Seyed H Mahmoudpour1, Abirami Veluchamy, Moneeza K Siddiqui, Folkert W Asselbergs, Patrick C Souverein, Catherine E de Keyser, Albert Hofman, Chim C Lang, Alexander S F Doney, Bruno H Stricker, Anthonius de Boer, Anke H Maitland-van der Zee, Colin N A Palmer. 1. aDepartment of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University bDepartment of Cardiology, Division of Heart and Lungs, University Medical Center cDurrer Centre for Cardiovascular Research, Netherlands Heart Institute, Utrecht dDepartment of Epidemiology, Erasmus Medical Center, Rotterdam eDepartment of Respiratory Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands fCentre for Pharmacogenetics and Pharmacogenomics, Medical Research Institute, Ninewells Hospital and School of Medicine, University of Dundee, Dundee gInstitute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK hDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Abstract
OBJECTIVES: To identify single nucleotide polymorphisms (SNPs) associated with switching from an angiotensin-converting enzyme (ACE)-inhibitor to an angiotensin receptor blocker. METHODS: Two cohorts of patients starting ACE-inhibitors were identified within the Rotterdam Study in the Netherlands and the Genetics of Diabetes Audit and Research in Tayside Scotland study in Scotland. Cases were intolerant patients who switched from an ACE-inhibitor to an angiotensin receptor blocker and controls were individuals who used ACE-inhibitors continuously for at least 2 years and did not switch. Genome-wide association study (GWAS) using an additive model was run in these sets and the results were meta-analysed using Genome-Wide Association Meta Analysis software. RESULTS: A total of 972 cases out of 5161 ACE-inhibitor starters were identified. Eight SNPs within four genes reached the genome-wide association study significance level (P<5×10) in the meta-analysis [RNA binding protein, Fox-1 homolog (Caenorhabditis elegans), γ-aminobutyric acid receptor subunit γ-2, sarcoma (Src) homology 2 (SH2) B adaptor protein 1 and membrane bound O-acyltransferase domain containing 1]. The strongest associated SNP was located in an intron of RNA binding protein, Fox-1 homolog (Caenorhabditis elegans), which contains an RNA binding protein [rs2061538: minor allele frequency=0.16, odds ratio=1.52 (95% confidence interval: 1.32-1.76), P=6.2×10]. CONCLUSION: These results indicate that genetic variation in the above-mentioned genes may increase the risk of ACE-inhibitor-induced adverse reactions.
OBJECTIVES: To identify single nucleotide polymorphisms (SNPs) associated with switching from an angiotensin-converting enzyme (ACE)-inhibitor to an angiotensin receptor blocker. METHODS: Two cohorts of patients starting ACE-inhibitors were identified within the Rotterdam Study in the Netherlands and the Genetics of Diabetes Audit and Research in Tayside Scotland study in Scotland. Cases were intolerantpatients who switched from an ACE-inhibitor to an angiotensin receptor blocker and controls were individuals who used ACE-inhibitors continuously for at least 2 years and did not switch. Genome-wide association study (GWAS) using an additive model was run in these sets and the results were meta-analysed using Genome-Wide Association Meta Analysis software. RESULTS: A total of 972 cases out of 5161 ACE-inhibitor starters were identified. Eight SNPs within four genes reached the genome-wide association study significance level (P<5×10) in the meta-analysis [RNA binding protein, Fox-1 homolog (Caenorhabditis elegans), γ-aminobutyric acid receptor subunit γ-2, sarcoma (Src) homology 2 (SH2) B adaptor protein 1 and membrane bound O-acyltransferase domain containing 1]. The strongest associated SNP was located in an intron of RNA binding protein, Fox-1 homolog (Caenorhabditis elegans), which contains an RNA binding protein [rs2061538: minor allele frequency=0.16, odds ratio=1.52 (95% confidence interval: 1.32-1.76), P=6.2×10]. CONCLUSION: These results indicate that genetic variation in the above-mentioned genes may increase the risk of ACE-inhibitor-induced adverse reactions.
Authors: Alencia V Woodard-Grice; Amelia C Lucisano; James B Byrd; Elizabeth R Stone; William H Simmons; Nancy J Brown Journal: Pharmacogenet Genomics Date: 2010-09 Impact factor: 2.089
Authors: Antonio Grilo; María P Sáez-Rosas; Juan Santos-Morano; Elena Sánchez; Concha Moreno-Rey; Luis M Real; Reposo Ramírez-Lorca; María E Sáez Journal: Pharmacogenet Genomics Date: 2011-01 Impact factor: 2.089
Authors: Amy L Cilia La Corte; Angela M Carter; Gillian I Rice; Qing Ling Duan; Guy A Rouleau; Albert Adam; Peter J Grant; Nigel M Hooper Journal: Hum Mutat Date: 2011-09-12 Impact factor: 4.878
Authors: Seyed Hamidreza Mahmoudpour; Maarten Leusink; Lisa van der Putten; Ingrid Terreehorst; Folkert W Asselbergs; Anthonius de Boer; Anke H Maitland-van der Zee Journal: Pharmacogenomics Date: 2013-02 Impact factor: 2.533
Authors: M Arfan Ikram; Guy Brusselle; Mohsen Ghanbari; André Goedegebure; M Kamran Ikram; Maryam Kavousi; Brenda C T Kieboom; Caroline C W Klaver; Robert J de Knegt; Annemarie I Luik; Tamar E C Nijsten; Robin P Peeters; Frank J A van Rooij; Bruno H Stricker; André G Uitterlinden; Meike W Vernooij; Trudy Voortman Journal: Eur J Epidemiol Date: 2020-05-04 Impact factor: 8.082